Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 Update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

Annals of Hematology

Volumn 93, Issue 9, 2014, Pages 1449-1456

  Tacke, Daniela ^a,l,n   Buchheidt, Dieter ^b   Karthaus, Meinolf ^c   Krause, Stefan W ^d   Maschmeyer, Georg ^e   Neumann, Silke ^f   Ostermann, Helmut ^g   Penack, Olaf ^h   Rieger, Christina ^g   Ruhnke, Markus ^h   Sandherr, Michael ⁱ   Schweer, Katharina E ^a,l,n   Ullmann, Andrew J ^j   Cornely, Oliver A ^a,k,l,m  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Klinikum Neuperlach   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Ernst von Bergmann Klinikum   (Germany)

^f Interdisziplinäres Ambulantes Onkologiezentrum   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ Schwerpunktpraxis für Hämatologie und Onkologie   (Germany)

^j UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^k UNIVERSITY OF COLOGNE   (Germany)

^l UNIVERSITY OF COLOGNE   (Germany)

^m UNIVERSITY OF WITTEN HERDECKE   (Germany)

ⁿ Center for Integrated Oncology CIO Köln Bonn Medical Faculty University of Cologne ^*  (Germany)

more..

Author keywords

Amphotericin B; Antifungal prophylaxis; Fluconazole; Invasive fungal infection; Itraconazole; Liposomal; Posaconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; POLYENE; POSACONAZOLE; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; CANCER CHEMOTHERAPY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMIC MYCOSIS;

ADULT; ANTIFUNGAL AGENTS; AZOLES; CHEMOPREVENTION; GERMANY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; SOCIETIES, MEDICAL;

EID: 84905580152     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2108-y     Document Type: Review

References (41)

1. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8):1068-1075 (Pubitemid 44208634)
2. Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, Aloisi T, Irrera G, Bonini A, Picardi M, Caramatti C, Invernizzi R, Mattei D, Melillo L, de Waure C, Reddiconto G, Fianchi L, Valentini CG, Girmenia C, Leone G, Aversa F (2007) Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 45(9):1161-1170. doi:10.1086/522189 (Pubitemid 47580314)
3. Maschmeyer G, Haas A, Cornely OA (2007) Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67(11):1567-1601 (Pubitemid 47267298)
4. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20(1):133-163. doi:10.1128/cmr.00029-06 (Pubitemid 46167771)
5. Cornely OA, Bohme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Kruger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94(1):113-122. doi:10.3324/haematol. 11665
6. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M (2004) Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34(2):115-121. doi:10.1038/sj.bmt.1704543 (Pubitemid 39077101)
7. Ruping MJ, Vehreschild JJ, Cornely OA (2008) Patients at high risk of invasive fungal infections: when and how to treat. Drugs 68(14):1941-1962
8. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845-851. doi:10.1056/nejm199203263261301
9. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G (1993) Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. J Antimicrob Chemother 31(6):973-984 (Pubitemid 23218159)
10. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 171(6):1545-1552
11. Cornely OA, Vazquez J, De Waele J, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ (2013) Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. Mycoses. doi:10.1111/myc.12104
12. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23(4):317-322. doi:10.1007/s10096-004-1103-y (Pubitemid 38669942)
13. Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB, Wenzel RP, Seifert H (2013) Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. doi:10.1016/j.ijantimicag.2013.09.005
14. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407-1416. doi:10.1086/422312 (Pubitemid 39518200)
15. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolanos-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116(24):5111-5118
16. Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M, Yano T, Asakura S, Sunami K, Tabayashi T, Miyata A, Matsuoka K, Shinagawa K, Ikeda K, Matsuo K, Tanimoto M (2008) Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 88(5):588-595. doi:10.1007/s12185-008-0196-y
17. Girmenia C, Barosi G, Aversa F, Bacigalupo A, Barbui T, Baronciani D, Bosi A, Candoni A, Locasciulli A, Locatelli F, Menichetti F, Musso M, Viscoli C, Rambaldi A (2009) Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 49(8):1226-1236. doi:10.1086/605665
18. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G (2011) Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 155(3):318-327. doi:10.1111/j.1365- 2141.2011.08838.x
19. Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J (2012) Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant 18(10):1509-1516. doi:10.1016/j.bbmt. 2012.03.014
20. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103(4):1527-1533. doi:10.1182/blood-2003-08-2644 (Pubitemid 38168674)
21. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 138(9):705-713
22. Shen Y, Huang XJ, Wang JX, Jin J, Hu JD, Yu K, Wu DP, Wang SJ, Yu L, Chen XQ, Liu T, Liang YM, Chen FP, Li Y, Shen ZX (2013) Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study. Int J Clin Pharmacol Ther 51(9):738-745. doi:10.5414/cp201880
23. Winston DJ, Bartoni K, Territo MC, Schiller GJ (2011) Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 17(4):507-515. doi:10.1016/j.bbmt.2010.04.017
24. Sanchez-Ortega I, Patino B, Arnan M, Peralta T, Parody R, Gudiol C, Encuentra M, Fernandez de Sevilla A, Duarte RF (2011) Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 46(5):733-739. doi:10.1038/bmt.2010.185
25. Peterson L, Ostermann J, Rieger H, Ostermann H, Rieger CT (2013) Posaconazole prophylaxis - impact on incidence of invasive fungal disease and antifungal treatment in haematological patients. Mycoses 56(6):651-658. doi:10.1111/myc.12086
26. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348-359. doi:10.1056/NEJMoa061094 (Pubitemid 46148777)
27. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335-347 (Pubitemid 46148776)
28. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57(2):218-222 (Pubitemid 38223535)
29. Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Lopez J, Van Iersel M, Connelly N, Waskin H (2013) Phase 3 pharmacokinetics and safety study of posaconazole tablet in patients at risk for invasive fungal infection. Paper presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Berlin
30. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6):408-415 (Pubitemid 34851833)
31. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H (2011) Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer 19(1):19-26. doi:10.1007/s00520- 009-0783-3
32. Barreto JN, Beach CL, Wolf RC, Merten JA, Tosh PK, Wilson JW, Hogan WJ, Litzow MR (2013) The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. Am J Hematol 88(4):283-288. doi:10.1002/ajh.23388
33. Cattaneo C, Monte S, Algarotti A, Audisio E, Borlenghi E, Campiotti L, Cerqui E, Fanizza C, Giuliani R, Mico C, Rocconi R, Salvi A, Salvi F, Verga L, Levis A, Lambertenghi Deliliers G, Pogliani EM, Tognoni G, Rambaldi A, Rossi G (2011) A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study). J Antimicrob Chemother 66(9):2140-2145. doi:10.1093/jac/dkr271
34. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50(1):143-147. doi:10.1128/aac.50.1.143-147.2006 (Pubitemid 43042914)
35. Cornely OA, Ullmann AJ, Karthaus M (2005) Choosing a study population for the evaluation of antifungal prophylaxis. Clin Infect Dis 40(11):1699. doi:10.1086/429823, author reply 1699-1701
36. Walsh TJ, van Burik J-AH (2005) Reply to Cornely et al. Clin Infect Dis 40(11):1699-1701. doi:10.1086/429823
37. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Lowenberg B, Vulto A, Lugtenburg PJ, de Marie S (2008) Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 46(9):1401-1408. doi:10.1086/586739 (Pubitemid 351589940)
38. Hullard-Pulstinger A, Holler E, Hahn J, Andreesen R, Krause SW (2011) Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia. Onkologie 34(5):254-258. doi:10.1159/000327802
39. Chaftari AM, Hachem RY, Ramos E, Kassis C, Campo M, Jiang Y, Prince RA, Wang W, Raad II (2012) Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation 94(3):302-308. doi:10.1097/TP. 0b013e3182577485
40. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW (2006) Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 17(8):1306-1312 (Pubitemid 44288223)
41. Kish MA (2001) Guide to development of practice guidelines. Clin Infect Dis 32(6):851-854. doi:10.1086/319366 (Pubitemid 32524817)